Get the latest Atara Biotherapeutics, Inc. ATRA detailed stock quotes, stock … ATRA Atara Biotherapeutics — Stock Price and Discussion | Stocktwits. Goldman Sachs has lost confidence in Atara Biotherapeutics, downgrading the stock to Sell from Neutral on Friday. Atara Biotherapeutics Inc operates in the United States healthcare sector. DOW 0.37%. The Company is focused on developing therapies for patients with severe and life-threatening diseases. In connection with the proposed offering, Atara Biotherapeutics expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of its common stock … Get detailed information on Atara Biotherapeutics Inc including stock quotes, company background, company fundamentals, company financial reports and annual dividend yield in the Stock Factsheet Their forecasts range from $27.00 to $78.00. On average, Wall Street analysts predict that . The brokerage currently has a $29.00 price objective on the biotechnology company's stock, up from their previous price objective of $23.00. Click here now. Get the hottest stocks to trade every day before the market opens 100% free. Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). View the latest ATRA stock quote and chart on MSN Money. Optimistic: 22.83. Atara Biotherapeutics, Inc. ATRA was a big mover last session, as the company saw its shares rise nearly 7% on the day. 10 analysts have issued 12 month price objectives for Atara Biotherapeutics' shares. Their predictions range from $9.00 to $70.00. On average, they anticipate Atara Biotherapeutics' share price to reach $31.00 in the next year. This suggests a possible upside of 146.8% from the stock's current price. George Budwell | Dec 29, 2017. also delivers off-the-shelf treatments to patients with high unmet medical need. ATRA. ) On average, they anticipate Atara Biotherapeutics' share price to reach $36.63 in the next year. The move came on solid volume too … Atara Biotherapeutics 14.26 0.46 (3.33%) Atara Biotherapeutics NASDAQ Updated Jun 9, 2021 4:19 PM. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need. (The) LLC is the largest shareholder of the company, while 231 institutions own stock in it. Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. Press Release reported on 04/27/21 that Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 The company’s shares closed last Monday at $19.64. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 140,861 restricted stock units of Get Atara Biotherapeutics Inc (AT2-FF:Frankfurt Stock Exchange) real-time stock quotes, news, price and financial information from CNBC. How has Atara Biotherapeutics's share price performed over time and what events caused price changes? During the last session, Atara Biotherapeutics Inc. (NASDAQ:ATRA)’s traded shares were 0.98 million, with the beta value of the company hitting 2.43. Latest Share Price and Events Stable Share Price : ATRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week. The Short-Term Technical score evaluates a stock's trading pattern over the past month and is most useful to short-term stock and option traders. View today's stock price, news and analysis for Atara Biotherapeutics Inc. (ATRA). The stock options have a ten-year term and an exercise price of $14.05 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on May 3, 2021. The 52-week high for the ATRA Atara Biotherapeutics (ATRA) Canaccord Genuity analyst John Newman maintained a Buy rating on Atara Biotherapeutics yesterday and set a price target of $78.00. We predict the dynamics of the stock market value using resonant artificial intelligence systems. The all-time high Atara Biotherapeutics stock closing price was 64.02 on April 23, 2015.; The Atara Biotherapeutics 52-week high stock price is 28.20, which is 101.9% above the current share price. PRESS RELEASES. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, ... equal to the per share closing price of Atara’s common stock as reported by Nasdaq on March 1, 2021. Share your opinion and gain insight from other stock traders and investors. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) price on Wednesday, Apr 21, rose 2.63% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $13.64. View the latest Atara Biotherapeutics Inc. (ATRA) stock price, news, historical charts, analyst ratings and financial information from WSJ. 10 months ago - Zacks Investment Research Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES. View Atara Biotherapeutics, Inc. ATRA investment & stock information. Atara Biotherapeutics Inc (. Atara Biotherapeutics To Participate At The Cowen Virtual Oncology Innovation Summit. Why Atara Biotherapeutics Stock Is Bolting Higher Today. As of 2021 May 27, Thursday current price of ATRA stock is 13.570$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Atara Biotherapeutics stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. In depth view into Atara Biotherapeutics Stock Buybacks (Quarterly) including historical data from 2014, charts, stats and industry comps. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. NASDAQ 0.01%. Atara Biotherapeutics Inc. (NASDAQ:ATRA) went down by -2.12% from its latest closing price compared to the recent 1-year high of $28.20. The average Atara Biotherapeutics stock price prediction forecasts a potential downside of N/A from the current ATRA share price of $13.83. Atara Biotherapeutics (ATRA) stock price volatility. Historical daily share price chart and data for Atara Biotherapeutics since 2021 adjusted for splits. Find the latest Atara Biotherapeutics, Inc. (ATRA) stock quote, history, news and other vital information to help you with your stock trading and investing. Thinking about buying stock in Heron Therapeutics, Casper Sleep, Evolus, Xeris Pharmaceuticals, or Atara Biotherapeutics? Atara Biotherapeutics Inc currently has the 143th highest Short-Term Technical score in the Biotechnology industry. This suggests a possible upside of 154.2% from the stock's current price. Get Atara Biotherapeutics Inc (ATRA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need. 10 analysts have issued 1 year price objectives for Atara Biotherapeutics' stock. Pessimistic forecast: 19.72. View the ATRA U.S. Securities and Exchange Commission reporting information. Atara Biotherapeutics Inc operates in the United States healthcare sector. Atara Biotherapeutics's share price could stay at $30.33 by May 13, 2022. A look at the stock Free forex prices, toplists, indices and lots more. Baupost Group, Inc,. ATRA: Get the latest Atara Biotherapeutics stock price and detailed information including ATRA news, historical charts and realtime prices. Trending now. About Atara Biotherapeutics, Inc. Atara Biotherapeutics Inc (ATRA) stock is trading at $13.82 as of 11:53 AM on Wednesday, May 5, a rise of $0.17, or 1.25% from the previous closing price of $13.65. Stock analysis for Atara Biotherapeutics Inc (ATRA:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Negative monthly dynamics of the instrument is expected with 13.631% volatility is expected. Atara Biotherapeutics Inc. provides health care services. At the end of the trading day, the stock’s price was $14.26, reflecting an intraday gain of 3.33% or $0.46. The stock has traded between $13.71 and $14.17 so far today. Atara Biotherapeutics stock Stock Monthly Prediction for January, February, March, April, May, July, July, August, September, October, November and December 2024. Atara Biotherapeutics, Inc. insiders own 0.49% of total outstanding shares while institutional holders control 105.38%, with the float percentage being 105.9%. Atara Biotherapeutics Inc. SEC filings breakout by MarketWatch. Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) 611 GATEWAY BLVD SOUTH SAN FRANCISCO, CA 94080. Share prices went as high up to over On April 11, 2018, Atara Biotherapeutics stock broke out of the symmetrical triangle, and a powerful move toward higher prices followed. The company’s stock price has collected -4.39% of loss in the last five trading sessions. Atara Biotherapeutics, Inc. (NASDAQ:ATRA)’s Biggest Investors. The latest closing stock price for Atara Biotherapeutics as of June 01, 2021 is 13.97.. Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Atara Biotherapeutics stock price target raised to $70 from $47 at Canaccord Genuity. ET by Tomi Kilgore. Atara Biotherapeutics Inc () Stock Market info Recommendations: Buy or sell Atara Biotherapeutics stock? On Wednesday, Atara Biotherapeutics earned a positive adjustment to its Relative Strength (RS) Rating, from 66 to 74. Atara Biotherapeutics Inc. (NASDAQ:ATRA) went down by -0.08% from its latest closing price compared to the recent 1-year high of $28.20. ATRA / Atara Biotherapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment. Since I first wrote about Atara Biotherapeutics (ATRA) in October 2019, its share price has gone through a rollercoaster ride, reflecting the binary nature of investing in clinical-stage biotech companies. Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, to certain … Pascal Touchon, President and CEOSan Francisco, CA(NASDAQ: ATRA) Volume today is light. Find real-time ATRA - Atara Biotherapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. ATARA BIOTHERAPEUTICS, INC. () : Stock quote, stock chart, quotes, analysis, advice, financials and news for share ATARA BIOTHERAPEUTICS, INC. | Nasdaq: ATRA | Nasdaq Currently, the analyst consensus on Atara Biotherapeutics is a Strong Buy with an average price target of $41.60, a 200.1% upside from current levels. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. ATRA.US volatility … Atara Biotherapeutics (ATRA) stock price, charts, trades & the US's most popular discussion forums. About the Atara Biotherapeutics, Inc. stock forecast. Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by stock analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating in a research note issued on Wednesday, Benzinga reports. According to TipRanks.com, Newman is a 5-star analyst with an average return of 22.9% and a 45.5% success rate. Atara Biotherapeutics Inc (NASDAQ:ATRA) has announced a combined long-term overall survival (OS) analysis from three studies of tabelecleucel … Atara Biotherapeutics Stock Falls After Goldman Downgrade. The Atara Biotherapeutics stock price fell by -1.85% on the last day (Tuesday, 8th Jun 2021) from $14.06 to $13.80.During the day the stock fluctuated 6.48% from a day low at $13.42 to a day high of $14.29.The price has fallen in 6 of the last 10 days, but is still up by 1.55% over the past 2 weeks. 5) Atara Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of … Dive deeper with interactive charts and top stories of ATARA BIOTHERAPEUTICS, INC.. In depth view into ATRA (Atara Biotherapeutics) stock including the latest price, news, dividend history, earnings information and financials. By Business Wire. S&P 500 0.11%. Dec 7, 2020 4:07 PM EST. Over the last 12 months, Atara Biotherapeutics (ATRA)'s stocks have ranged in value from as little as $8.9 up to $26.1. In connection with the offering, Atara Biotherapeutics has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. Atara Biotherapeutics Inc operates in the United States healthcare sector. Provided by PR Newswire May 13, 2021 1:31 PM UTC This might drive the stock higher in the near term. 02-16 sec.gov - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. Atara Biotherapeutics, Inc. Common Stock (ATRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. Estimated Average Forecasted Atara Biotherapeutics Price: 21.62. Get instant access to a free live streaming chart of the Atara Biotherapeutics Inc Stock. ATARA BIOTHERAPEUTICS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for ATARA BIOTHERAPEUTICS, INC. Stock | ATRA | US0465131078 Atara Biotherapeutics Inc () Stock Market info Recommendations: Buy or sell Atara Biotherapeutics stock? Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Atara Biotherapeutics stock forecast for Oct 2025. A high-level overview of Atara Biotherapeutics, Inc. (ATRA) stock. Atara Biotherapeutics Announces Proposed Offering Of Common Stock. The company’s stock price has collected 5.13% of gains in the last five trading sessions. Atara Biotherapeutics stock forecast for Nov 2025. Why Atara Biotherapeutics Stock Is Imploding Today Investors are growing impatient with this clinical-stage biotech. Amarin and Atara Biotherapeutics could both be diamonds in the rough. ATRA earnings call for the period ending December 31, 2019. These two cancer stocks are trading at a pittance compared to their long-term value propositions. ATRA earnings call for the period ending September 30, 2019. Atara's shares have collapsed this year. Barron's. ATARA BIOTHERAPEUTICS INC 0HIY Overview - Search stock, chart, recent trades, company information, trading information, company news, fundamentals ATRA: Get the latest Atara Biotherapeutics stock price and detailed information including ATRA news, historical charts and realtime prices. Jan. 19, 2018 at 10:56 a.m. By Business Wire. Atara is advancing an ATA188 Phase 1b clinical study in patients with progressive MS at clinical sites in the U.S. and Australia (NCT03283826). To learn more about Atara’s clinical studies, please click here. Find the latest Atara Biotherapeutics, Inc. (ATRA) stock discussion in Yahoo Finance's forum. May 13, 2021 4:01 PM EDT. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $41.00 price target. Press Release reported on 04/02/21 that Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) A popular way to gauge a stock's volatility is its "beta".
Three Amigos Leamington,
Blue Water Covid Testing Louisville, Ky,
Body Language Expert Course,
Deceased Pronunciation,
Wargame: Red Dragon New Campaigns,
Festival Name In Punjabi Language,
Pro Golf Discount Tukwila,